Optimizing Biologic Selection in Severe Asthma: Integrating Guidelines, Equity, and Patient-Centered Care
LIVE MEETINGS
up to 1.25 AMA PRA Credit
This educational activity is supported by an independent educational grant from GSK.
Maximum Credit Amount: 1.25
Credit Type: ACCME, ANCC
Release: October 11, 2026
Expiration: October 11, 2026
To view the AI Simulation and claim credit, click the "Get CME Credit" to log in or create your free account.
Live Meetings
Overview
Learning Objectives
CME/ Information
Faculty and Disclosures
Instructions
September
17
2026
Southeastern Allergy, Asthma & Immunology Society Annual Conference
Hilton Head Island, SC
The Omni Hilton Head
Palmetto Ballroom
7:00 pm - 8:15 pm EST
The Omni Hilton Head
Palmetto Ballroom
7:00 pm - 8:15 pm EST
Sunday
October
11
2026
2026 Southern California
Allergy Conference
Allergy Conference
Oceanside, CA
The Seabird Resort
1:00 to 2:00 PM PT
The Seabird Resort
1:00 to 2:00 PM PT
October
18
2026
Southern California
Allergy Conference
Southern California
Allergy Conference
Oceanside, CA
The Seabird Resort
Room TBD
Time TBD
The Seabird Resort
Room TBD
Time TBD
To view the AI Simulation and claim credit, click the "Get CME Credit" to log in or create your free account.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Utilize understanding of severe asthma pathophysiology encompassing Type 2 inflammatory pathways, IL-5-mediated mechanisms, and biomarker-based phenotypic classification to guide precision medicine approaches in clinical practice.
- Employ biomarker-driven phenotyping approaches to determine appropriate candidates for biologic therapies, integrating recommendations from the GINA 2025 and CHEST 2025 guidelines along with novel therapeutic agents.
- Implement collaborative decision-making techniques that ensure biologic therapy selections reflect individual patient priorities and preferences within the context of severe asthma management.
- Apply systematic approaches for identifying and addressing comorbid conditions as part of an individualized treatment plan for patients living with severe asthma.
- Recognize social determinants of health that influence severe asthma outcomes.
- Develop actionable strategies to address inequities in care delivery.
Accredited Provider
This activity is jointly provided by Global Education Group and Iridium Continuing Education.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Global Education Group and Iridium CE. Global Education Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation
Global Education Group designates this live material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurse Contact Hours Designation
Global Education Group designates this continuing education activity for 1.25 contact hour(s) including 0.0 pharmacotherapeutic contact hour(s).
Faculty, Staff, and Planners’ Disclosures
The planners and managers at Global Education Group and Iridium CE have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use
This educational
activity may contain discussion of published and/or investigational uses of
agents that are not indicated by the FDA. Global and Iridium CE do not
recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosures of Relevant Financial Relationship(s)
Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by Joint Accreditation and all other accrediting bodies, as applicable, stating those activities where CE credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited CE program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are appropriately identified as relevant by Global. All relevant financial relationships have been mitigated in advance of delivery of the activity to learners.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
IWAA faculty Presenter:
Suzanne Ngo, MD
Assistant Professor
Department of Medicine-Allergy/Clinical Immunology
University of Colorado
Aurora, CO
Disclosures
Department of Medicine-Allergy/Clinical Immunology
University of Colorado
Aurora, CO
Disclosures
Stock Shareholder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed):
AbbVie, Inc., Alnylam Pharmaceuticals, Inc., Amgen, Inc.,Biogen, Inc., Bristol Myers Squibb Co., Gilead Sciences, Inc., Incyte Corp., Kenvue, Inc., Eli Lilly & Co., Merck & Co., Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc., Viatris, Inc., Align Technology, Inc., Becton, Dickinson & Co., Boston Scientific Corp., Edwards Lifesciences Corp., GE Healthcare Technologies, Inc., Intuitive Surgical, Inc., Johnson & Johnson, Insulet Corp., ResMed, Inc., Solventum Corp., STERIS Plc, West Pharmaceutical Services, Inc., Quest Diagnostics, Inc., Danaher Corp., Labcorp Holdings, Inc., Revvity, Inc., Bio-Techne Corp., Thermo Fisher Scientific, Inc., Waters Corp., Cardinal Health, Inc., Cencora, Inc., CVS Health Corp., Henry Schein, Inc., McKesson Corp.
AbbVie, Inc., Alnylam Pharmaceuticals, Inc., Amgen, Inc.,Biogen, Inc., Bristol Myers Squibb Co., Gilead Sciences, Inc., Incyte Corp., Kenvue, Inc., Eli Lilly & Co., Merck & Co., Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc., Viatris, Inc., Align Technology, Inc., Becton, Dickinson & Co., Boston Scientific Corp., Edwards Lifesciences Corp., GE Healthcare Technologies, Inc., Intuitive Surgical, Inc., Johnson & Johnson, Insulet Corp., ResMed, Inc., Solventum Corp., STERIS Plc, West Pharmaceutical Services, Inc., Quest Diagnostics, Inc., Danaher Corp., Labcorp Holdings, Inc., Revvity, Inc., Bio-Techne Corp., Thermo Fisher Scientific, Inc., Waters Corp., Cardinal Health, Inc., Cencora, Inc., CVS Health Corp., Henry Schein, Inc., McKesson Corp.
SEAAIS faculty Presenter:
Michael S. Blaiss, MD
Clinical Professor
Allergy/Immunology and Rheumatology
Medical College of Georgia at Augusta University
Augusta, GA
Disclosures
Consulting Fee (e.g., Advisory Board):
AstraZeneca, Bayer, Begin Health, GSK, Kenvue, Lilly, Nasus Pharma, Novartis, Ophelia, Regeneron, Sanofi
AstraZeneca, Bayer, Begin Health, GSK, Kenvue, Lilly, Nasus Pharma, Novartis, Ophelia, Regeneron, Sanofi
SDAS faculty Presenter:
Marc Riedl, MD, MS
Professor of Medicine
HAE Community Endowed Chair, Clinical Service Chief
Division of Allergy & Immunology
University of California, San Diego
San Diego, CA
HAE Community Endowed Chair, Clinical Service Chief
Division of Allergy & Immunology
University of California, San Diego
San Diego, CA
Disclosures
Consulting Fee (e.g., Advisory Board): ADARx, Astria, Biocryst, Celldex, CSL Behring, Grifols, Intellia, Ionis, Kalvista, Novartis, Pharming, Pharvaris, Sanofi-Regeneron, Takeda
Consulting Fee (e.g., Advisory Board): ADARx, Astria, Biocryst, Celldex, CSL Behring, Grifols, Intellia, Ionis, Kalvista, Novartis, Pharming, Pharvaris, Sanofi-Regeneron, Takeda
Contracted Research (Principal Investigators must provide information, even if received by the institution): Astria, ADARx, Biocryst, CSL Behring, Intellia, Ionis, Kalvista, Pharvaris, Takeda
Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete the activity, application for credit and evaluation form. Participants must also score at least 70% on the post-test.
A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.
Fee Information and Refund/Cancellation Policy
There is no fee for this educational activity.
Global Contact Information
For information about the Joint Accreditation, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
System Requirements
Program Overview
Optimizing Biologic Selection in Severe Asthma: Integrating Guidelines, Equity, and Patient-Centered Care is a live CME/CE activity designed to improve clinician competence in biomarker-guided phenotyping, biologic selection, shared decision-making, and equitable severe asthma care. Through expert faculty education and immersive Conversational AI patient simulations, learners will engage in interactive, case-based experiences focused on guideline-concordant treatment selection, comorbidity management, culturally competent communication, and individualized care strategies for patients with severe asthma.
Target Audience
The primary audience for this activity includes pulmonologists, critical care specialists, and allergists/immunologists, as well as nurse practitioners and physician assistants who specialize in the diagnosis and management of severe asthma.
Supporter Acknowledgement
This educational activity is supported by an independent educational grant from GSK.
Copyright © 2026
Legal
Stay Informed
To receive updates as soon as the new dates are confirmed, please share your email.
We appreciate your ongoing interest and look forward to keeping you informed with the latest details!
We appreciate your ongoing interest and look forward to keeping you informed with the latest details!
Thank you!
✅ You’re confirmed!
Thank you for confirming.
You’ll receive reminder emails for the next LGS CME/CE session, including full access details.
We look forward to your participation.
Thank you for confirming.
You’ll receive reminder emails for the next LGS CME/CE session, including full access details.
We look forward to your participation.
Earn up to 1.5 AMA PRA Credit
The OX2R Era Is Here. Is Your NT1 Diagnosis?
Phoenix, AZ | October 18, 2026 | 12:00 - 1:15 Phoenix Time
Overview
Learning Objectives
CME/ Information
Faculty and Disclosures
Instructions
AI Statement
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Identify the full NT1 symptom pentad and the systemic clinical burden of orexin deficiency.
- Apply the cataplexy interrogation question at the CPAP non-response encounter.
- Differentiate NT1 from NT2, idiopathic hypersomnia, and common misdiagnoses using the defining diagnostic criterion of cataplexy or CSF hypocretin-1 <110 pg/mL.
- Distinguish NT1 from medication-induced and primary psychiatric EDS using ICSD-3 criteria when psychiatric comorbidity complicates evaluation of excessive daytime sleepiness.
- Apply evidence-based PSG/MSLT diagnostic protocols, including medication washout requirements, SOREMP interpretation, and CSF hypocretin-1 <110 pg/mL as a standalone NT1 diagnostic criterion per ICSD-3.
- Integrate SDoH-informed screening, navigator referral pathways, and telehealth-compatible approaches to reduce diagnostic delay in NT1 across diverse patient populations.
- Individualize NT1 treatment selection using an SDM framework informed by the limitations of current pharmacotherapy and the mechanism of emerging OX2R-directed therapies.
Accredited Provider
This activity is jointly provided by Global Education Group and Iridium Continuing Education.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Global Education Group and Iridium CE. Global Education Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation
Global Education Group designates this live material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurse Contact Hours Designation
Global Education Group designates this continuing education activity for 1.5 contact hour(s) including 0.0 pharmacotherapeutic contact hour(s).
Faculty, Staff, and Planners’ Disclosures
The planners and managers at Global Education Group and Iridium CE have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use
This educational
activity may contain discussion of published and/or investigational uses of
agents that are not indicated by the FDA. Global and Iridium CE do not
recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosures of Relevant Financial Relationship(s)
Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by Joint Accreditation and all other accrediting bodies, as applicable, stating those activities where CE credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited CE program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are appropriately identified as relevant by Global. All relevant financial relationships have been mitigated in advance of delivery of the activity to learners.
The faculty have the following relevant financial relationships with ineligible companies:
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
faculty Presenters:
Clete A. Kushida, MD, PhD
Professor of Psychiatry and Behavioral Sciences (Sleep
Medicine)
Chief of the Stanford Division of Sleep Medicine
Medical Director of the Stanford Sleep Medicine Center
Associate Chair and Professor in the Stanford Department of
Psychiatry and Behavioral Sciences at the Stanford
University Medical Center,
Director of the Stanford Human Sleep Research Laboratory
Disclosures
Disclosures
Consulting Fee (e.g., Advisory Board): Avadel Pharmaceuticals, SoundHealth Inc.. Alkermes, Lilly, Lundbeck, Apnimed, Eisai
Contracted Research (Principal Investigators must provide information, even if received by the institution): Samsung
Stock Shareholder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed): Vivos Therapeutics
Stock Option Holder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed): Asleep, SoundHealth Inc.
Atul Malhotra, MD
Division of Pulmonary, Critical Care, Sleep Medicine and Physiology, San Diego (UCSD)
University of California
La Jolla, CA
Disclosures
University of California
La Jolla, CA
Disclosures
Consulting Fee (e.g., Advisory Board): Eli Lilly, Zoll, Livanova, Sunrise, Pfizer, Aerin
Patient Advocate:
Casey McGarry
Patient Advocate & Rare Disease Advocacy Consultant
Volunteer Peer Support Group Facilitator, Wake Up Narcolepsy Oklahoma City, Oklahoma
Volunteer Peer Support Group Facilitator, Wake Up Narcolepsy Oklahoma City, Oklahoma
Disclosures
Consulting Fee (e.g., Advisory Board): Takeda Pharmaceuticals USA, Inc ended March 31, 2026
Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete the activity, application for credit and evaluation form. Participants must also score at least 70% on the post-test.
A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.
Fee Information and Refund/Cancellation Policy
There is no fee for this educational activity.
Global Contact Information
For information about the Joint Accreditation, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
System Requirements
Program Overview
Narcolepsy Type 1 (NT1) remains substantially underrecognized, resulting in significant diagnostic delays and missed opportunities for timely treatment. This educational activity combines expert faculty presentations, a patient perspective, and an interactive AI-powered patient simulation to strengthen clinicians' ability to recognize NT1, apply evidence-based diagnostic strategies, address barriers to care, and integrate emerging therapies into patient-centered management. Through realistic clinical scenarios and practical discussion, participants will gain strategies to improve diagnostic accuracy and optimize outcomes for patients with NT1.
Target Audience
The primary audience for this activity includes pulmonologists, sleep specialists, primary care physicians, internists, hospitalists, nurse practitioners, physician assistants, and respiratory therapists involved in the diagnosis and management of narcolepsy.
Supporter Acknowledgement
This educational activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Use of artificial intelligence in this activity
This activity is jointly provided by Global Education Group (Global) and Iridium Continuing Education (IridiumCE). It includes an AI-simulated patient. You will talk with a virtual patient whose responses are generated by artificial intelligence. The patient's story is based on the lived experience of Casey McGarry, a patient living with narcolepsy type 1, and is shared with his consent. He has reviewed and approved how his experience is portrayed.
How the AI is controlled.
The simulated patient responds only within a case written and approved by the activity faculty, Clete A. Kushida, MD, PhD, and Atul Malhotra, MD. Clinical content is limited to a closed set of sources: current clinical guidelines and the references cited in the activity slides (see the reference list), current as of October 12, 2026.
The AI does not search the internet. It does not give you diagnostic or treatment recommendations. Before release, the faculty and the IridiumCE and Global Education Group planners, tested the simulation for accuracy, completeness, balance and freedom from commercial bias on October 12, 2026.
Platform: Patient dialogue is generated using OpenAI's GPT-4.1 model (gpt-4.1-2025-04-14). The patient's video avatar is powered by HeyGen.
Independence. Global, as the accredited provider, is responsible for all content in this activity, including what the AI generates.
The AI does not search the internet. It does not give you diagnostic or treatment recommendations. Before release, the faculty and the IridiumCE and Global Education Group planners, tested the simulation for accuracy, completeness, balance and freedom from commercial bias on October 12, 2026.
Platform: Patient dialogue is generated using OpenAI's GPT-4.1 model (gpt-4.1-2025-04-14). The patient's video avatar is powered by HeyGen.
Independence. Global, as the accredited provider, is responsible for all content in this activity, including what the AI generates.
This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc. Takeda had no role in writing the case, configuring the AI, or deciding how it is scored. Scores reflect your clinical reasoning and communication, not which treatment is chosen. No product advertising is provided within activity.
Limitations. AI can make mistakes. Responses may occasionally be incomplete, worded unexpectedly, or wrong. Known limitations for this case, e.g. the patient cannot respond to physical-exam maneuvers outside the menu. This simulation is for educational purposes only and is not clinical guidance. The learners remain responsible for their own clinical decisions. If a response seems inaccurate or inappropriate, select Flag.
A clinical reviewer will review it.
Data. All conversation and scores are recorded so we can give personalized feedback, award credit, and evaluate and improve the activity.
Data. All conversation and scores are recorded so we can give personalized feedback, award credit, and evaluate and improve the activity.
Transcripts are stored apart from your name and analyzed in de-identified form. Iridium Continuing Education holds the transcripts in secure, access-controlled systems.
Learner data is never sold, never shared with commercial supporters except as aggregate de-identified results, and never used to train outside AI models.
Your voice is used only to transcribe your words. Your voice is never copied, cloned or used to create a synthetic voice. Please do not enter information about real patients.
Compliance. This use of AI follows the Accreditation Council for Continuing Medical Education (ACCME) Guidance on the Responsible Use of Artificial Intelligence in Accredited Continuing Education (January 30, 2026) and its Urgent Alert on the Use of AI in Accredited CE (April 14, 2026). It also meets the ACCME Standards for Integrity and Independence in Accredited Continuing Education.
Questions? Contact info@iridiumce.com.
Pre-Meeting Simulation: The OX2R Era Is Here. Is Your NT1 Diagnosis?
AI Simulation: The OX2R Era Is Here. Is Your NT1 Diagnosis?